Skip to content
Bavisant
Bavisant is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Attention deficit disorder with hyperactivityD001289EFO_0003888F90224
AlcoholismD000437EFO_0003829F10.111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD01059933
Healthy volunteers/patients33
Drug interactionsD00434722
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBAVISANT
INNbavisant
Description
Bavisant is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Classification
Small molecule
Drug classhistamine H3 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1
Identifiers
PDB
CAS-ID929622-08-2
RxCUI
ChEMBL IDCHEMBL2103862
ChEBI ID
PubChem CID
DrugBank
UNII ID9827P7LFVH (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 14 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details